Yr Athro Neil Robertson
(Translated he/him)

MBBS FRCP MD

Professor of Neurology, Division of Psychological Medicine and Clinical Neurosciences

Sglerosis Ymledol: Dros yr 8 mlynedd diwethaf rydym wedi adeiladu gwasanaeth clinigol cynhwysfawr ar gyfer MS ar draws de-ddwyrain Cymru, gan integreiddio prosiectau ymchwil academaidd a gweithio'n agos gyda staff y GIG. Mae hyn wedi ein galluogi i ddatblygu adnodd epidemiolegol mawr ar gyfer astudiaethau trawsdoriadol a hydredol o Sglerosis Ymledol yn ogystal â datblygu biofanc cyfochrog ar gyfer samplau DNA, serwm a CSF. Ein nod hirdymor yw nodi marcwyr clinigol a biocemegol dibynadwy prognosis er mwyn cyfeirio ymyriadau therapiwtig mewn clefyd sydd â chanlyniad hynod amrywiol. Rydym wedi datblygu cydweithrediadau â Phrifysgol Caergrawnt a'r IMSGC ar gyfer astudiaethau i fod yn agored i niwed genetig mewn MS ac mae gennym hefyd raglen o dreialon clinigol.

Ataxia: Yn ddiweddar rydym wedi cwblhau cyfres o astudiaethau genetig ac epidemiolegol i atacsia cychwyn hwyr yn ne Cymru gan nodi a dogfennu mynychder, etioleg a darparu esboniad am amlder clefydau rhai is-setiau yn y boblogaeth hon.

Date
Type

2022

Beesley, R. et al. 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68, article number: 104121. (10.1016/j.msard.2022.104121)
Hawken, J. and Robertson, N. 2022. Sleep disorders in Parkinson’s disease. Journal of Neurology 269, pp. 6685-6687. (10.1007/s00415-022-11403-5)
Walz, L., Brooks, J. C., Shavelle, R. M., Robertson, N. and Harding, K. E. 2022. Life expectancy in multiple sclerosis by EDSS score. Multiple Sclerosis and Related Disorders 68, article number: 104219. (10.1016/j.msard.2022.104219)
Miah, L. and Robertson, N. 2022. The gut microbiome: neurological development and disease. Journal of Neurology 269(10), pp. 5682-5684. (10.1007/s00415-022-11334-1)
Kreft, K. L. and Robertson, N. P. 2022. Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment. Journal of Neurology 269(9), pp. 5192-5193. (10.1007/s00415-022-11300-x)
Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64, article number: 103937. (10.1016/j.msard.2022.103937)
Gailani, G. and Robertson, N. P. 2022. Clinical patterns in CADASIL. Journal of Neurology 269(8), pp. 4575-4577. (10.1007/s00415-022-11261-1)
Hrastelj, J. and Robertson, N. P. 2022. Socioeconomic status in neurological disorders: a modifiable risk factor?. Journal of Neurology 269(6), pp. 3385-3386. (10.1007/s00415-022-11123-w)
Schroeder, B. E. and Robertson, N. P. 2022. Clinical trials for cerebellar ataxia. Journal of Neurology 269(5), pp. 2819–2821. (10.1007/s00415-022-11088-w)
Hrastelj, J. and Robertson, N. P. 2022. A role for the Epstein–Barr virus in multiple sclerosis aetiology?. Journal of Neurology 269(7), pp. 3962-3963. (10.1007/s00415-022-11177-w)
Allman, M., Tallantyre, E. and Robertson, N. P. 2022. Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies. Journal of Neurology 269(4), pp. 2259-2261. (10.1007/s00415-022-11053-7)
Thomas, R., Wynford-Thomas, R. and Robertson, N. P. 2022. Advances in the use of stem cell transplants in the treatment of multiple sclerosis. Journal of Neurology 269(2), pp. 1065–1067. (10.1007/s00415-021-10927-6)
Wood, C. H., Robertson, N., Min Htet, Z. and Tallantyre, E. 2022. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. Multiple Sclerosis and Related Disorders 58, article number: 103492. (10.1016/j.msard.2022.103492)
Talaei, M. and Robertson, N. P. 2022. Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy. Journal of Neurology 269(1), pp. 534-536. (10.1007/s00415-021-10908-9)
Cauchi, M., Ball, H., Ben-Shlomo, Y. and Robertson, N. 2022. Interpretation of vaccine associated neurological adverse events: a methodological and historical review. Journal of Neurology 269, pp. 493-503. (10.1007/s00415-021-10747-8)
Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91(1), pp. 89-100. (10.1002/ana.26251)

2021

Williams, S., Wynford-Thomas, R. and Robertson, N. P. 2021. Long-COVID: neurological manifestations and management. Journal of Neurology 268(12), pp. 4915–4917. (10.1007/s00415-021-10847-5)
Hrastelj, J. and Robertson, N. P. 2021. Vaccine-induced immune thrombosis and thrombocytopaenia: incidence, mechanism and treatment. Journal of Neurology 268(11), pp. 4396-4397. (10.1007/s00415-021-10825-x)
Al-Ansari, A. and Robertson, N. P. 2021. Autoimmune encephalitis: clinical presentation, investigation and treatment. Journal of Neurology 268(10), pp. 3935–3937. (10.1007/s00415-021-10800-6)
Massey, T. H. and Robertson, N. P. 2021. Medication-overuse headache: causes, consequences and management. Journal of Neurology 268(9), pp. 3505–3507. (10.1007/s00415-021-10720-5)
Al-Ansari, A. and Robertson, N. P. 2021. Postural orthostatic tachycardia syndrome: insights into pathogenesis and treatment. Journal of Neurology 268(7), pp. 2616–2618. (10.1007/s00415-021-10649-9)
Winter, M., Tallantyre, E. C., Brice, T. A. W., Robertson, N. P., Jones, D. K. and Chamberland, M. 2021. Tract-specific MRI measures explain learning and recall differences in multiple sclerosis. Brain Communications 3(2), article number: fcab065. (10.1093/braincomms/fcab065)
Hrastelj, J. et al. 2021. CSF-resident CD4+ T-cells display a distinct gene expression profile with relevance to immune surveillance and multiple sclerosis. Brain Communications (10.1093/braincomms/fcab155)
Hares, K. et al. 2021. KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology 268, pp. 2175-2184. (10.1007/s00415-020-10373-w)
Lipp, I. et al. 2021. Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: a behavioural and MRI study. Multiple Sclerosis 7(7), pp. 1088-1101. (10.1177/1352458520943788)
Cauchi, M. and Robertson, N. P. 2021. Neurology and vaccinations: considerations in the context of COVID-19/SARS-COV-2. Journal of Neurology 268, pp. 2002-2004. (10.1007/s00415-021-10513-w)
Massey, T. H. and Robertson, N. P. 2021. Spontaneous intracranial hypotension: features, diagnosis and management. Journal of Neurology 268(4), pp. 1555-1557. (10.1007/s00415-021-10500-1)

2020

Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26(14), pp. 1929-1937. (10.1177/1352458519887905)
Willis, M. D. and Robertson, N. P. 2020. Multiple sclerosis: early indicators of disease and assessing future risk. Journal of Neurology 267(11), pp. 3436-3438. (10.1007/s00415-020-10239-1)
Naughton, M. et al. 2020. CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis. Journal of Neuroinflammation 17(1), article number: 349. (10.1186/s12974-020-02025-7)
Walton, C. et al. 2020. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis 26(14), pp. 1816-1821. (10.1177/1352458520970841)
Al-Ansari, A. and Robertson, N. P. 2020. Cerebral venous thrombosis: clinical predictors and emerging treatments. Journal of Neurology 267(10), pp. 3112–3114. (10.1007/s00415-020-10180-3)
Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417, article number: 117079. (10.1016/j.jns.2020.117079)
Wynford-Thomas, R. and Robertson, N. P. 2020. Emerging treatments for neuromyelitis optica spectrum disorder. Journal of Neurology 267(9), pp. 2771-2773. (10.1007/s00415-020-10083-3)
Saxena, G. et al. 2020. Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis. Neurology, Neuroimmunology and Neuroinflammation 7(4), article number: e767. (10.1212/NXI.0000000000000767)
Hu, M. and Robertson, N. P. 2020. Physical activity as a risk factor for amyotrophic lateral sclerosis-findings from three large European cohorts. Journal of Neurology 267(7), pp. 2173-2175. (10.1007/s00415-020-09995-x)
Yeo, T. et al. 2020. A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application. Scientific Reports 10, article number: 12381. (10.1038/s41598-020-69119-3)
Tallantyre, E., Castle, D., Karamura, P., Brice, T., Joseph, F., Harding, K. and Robertson, N. 2020. Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. Multiple Sclerosis and Related Disorders 42, article number: 102056. (10.1016/j.msard.2020.102056)
Pryce-Roberts, A., Talaei, M. and Robertson, N. P. 2020. Neurological complications of COVID-19: a preliminary review. Journal of Neurology 267(6), pp. 1870-1873. (10.1007/s00415-020-09941-x)
Willis, M. D. and Robertson, N. P. 2020. Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2. Journal of Neurology 267(5), pp. 1567-1569. (10.1007/s00415-020-09822-3)
McLauchlan, D. and Robertson, N. P. 2020. Chronic traumatic encephalopathy: quantifying risk and clarifying pathogenesis. Journal of Neurology 267(3), pp. 870-872. (10.1007/s00415-020-09734-2)
Massey, T. H. and Robertson, N. P. 2020. Restless legs syndrome: causes and consequences. Journal of Neurology 267(2), pp. 575-577. (10.1007/s00415-019-09682-6)

2019

Davda, N., Tallantyre, E. and Robertson, N. P. 2019. Early MRI predictors of prognosis in multiple sclerosis. Journal of Neurology 266(12), pp. 3171-3173. (10.1007/s00415-019-09589-2)
Al-Ansari, A. and Robertson, N. P. 2019. Cluster headache: an overview of established and emerging treatments. Journal of Neurology 266(11), pp. 2890-2892. (10.1007/s00415-019-09548-x)
Castle, D. and Robertson, N. P. 2019. Treatment of progressive multifocal leukoencephalopathy. Journal of Neurology 266(10), pp. 2587-2589. (10.1007/s00415-019-09501-y)
Jones, L. et al. 2019. A case of treatment resistance and complications in a patient with stiff person syndrome and cerebellar ataxia. Tremor and Other Hyperkinetic Movements 9 (10.7916/tohm.v0.677)
Castle, D. and Robertson, N. P. 2019. Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neurology 266(9), pp. 2338-2340. (10.1007/s00415-019-09485-9)
Willis, M. D. and Robertson, N. P. 2019. Neurotoxicity of novel cancer immunotherapies. Journal of Neurology 266(8), pp. 2087-2089. (10.1007/s00415-019-09444-4)
Muller, I., Moran, C., Lecumberri, B., Decallonne, B., Robertson, N., Jones, J. and Dayan, C. 2019. 2019 European thyroid association guidelines on the management of thyroid dysfunction following immune reconstitution therapy. European Thyroid Journal 8(4), pp. 173-185. (10.1159/000500881)
Lipp, I. et al. 2019. Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis. Human Brain Mapping 40(10), pp. 2917-2932. (10.1002/hbm.24568)
Hu, M., Muhlert, N., Robertson, N. and Winter, M. 2019. Perceived fatigue and cognitive performance change in multiple sclerosis: Uncovering predictors beyond baseline fatigue. Multiple Sclerosis and Related Disorders 32, pp. 46-53. (10.1016/j.msard.2019.04.011)
Al-Ansari, A. and Robertson, N. P. 2019. Autoimmune encephalitis: frequency and prognosis. Journal of Neurology 266(5), pp. 1287-1289. (10.1007/s00415-019-09273-5)
Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25(4), pp. 523-531. (10.1177/1352458518758927)
Willis, M. and Robertson, N. 2019. Technology-assisted recovery of walking after spinal cord injury. Journal of Neurology 266(4), pp. 1046-1048. (10.1007/s00415-019-09227-x)
Harding, K. E., Wardle, M., Carruthers, R., Robertson, N., Zhu, F., Kingwell, E. and Tremlett, H. 2019. Socioeconomic status and disability progression in multiple sclerosis: a multinational study. Neurology 92(13), pp. e1497-e1506. (10.1212/WNL.0000000000007190)
Harding, K. et al. 2019. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurology 76(5), pp. 536-541. (10.1001/jamaneurol.2018.4905)
Palace, J. et al. 2019. Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme. Journal of Neurology, Neurosurgery and Psychiatry 90(36), pp. 251-260. (10.1136/jnnp-2018-318360)
Whittam, D. H. et al. 2019. Rituximab in neurological disease: principles, evidence and practice. Practical Neurology 19(1), pp. 5-10. (10.1136/practneurol-2018-001899)
Smith, M. D., Schwartz, S. and Robertson, N. P. 2019. Imaging in the diagnosis of progressive supranuclear palsy. Journal of Neurology 266(2), pp. 545-547. (10.1007/s00415-018-9148-5)
Brown, J. W. L. et al. 2019. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. Journal of the American Medical Association 321(2), pp. 175-187. (10.1001/jama.2018.20588)
Harding, K. E. and Robertson, N. P. 2019. New rare genetic variants in multiple sclerosis. Journal of Neurology 266(1), pp. 278-280. (10.1007/s00415-018-9128-9)

2018

Muller, I. et al. 2018. Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years.. Thyroid 28(12), pp. 1682-1693. (10.1089/thy.2018.0232)
Tallantyre, E. C., Robertson, N. P. and Jolles, S. 2018. Secondary antibody deficiency in neurology. Current Opinion in Allergy and Clinical Immunology 18(6), pp. 481-488. (10.1097/ACI.0000000000000485)
Beesley, R. et al. 2018. Impact of the 2017 revisions to McDonald criteria on the diagnosis of Multiple Sclerosis. Multiple Sclerosis 24(13), pp. 1786-1787. (10.1177/1352458518778007)
Willis, M. D. et al. 2018. Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis 24(13), pp. 1779-`782. (10.1177/1352458518790391)
Al-Ansari, A. and Robertson, N. P. 2018. Anti-epileptics and pregnancy: an update. Journal of Neurology 265(11), pp. 2749-2751. (10.1007/s00415-018-9058-6)
Harding, K. et al. 2018. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple Sclerosis and Related Disorders 25, pp. 186-191. (10.1016/j.msard.2018.08.001)
Tallantyre, E. C. et al. 2018. How common is truly benign MS in a UK population?. Journal of Neurology, Neurosurgery and Psychiatry 90, pp. 522-528. (10.1136/jnnp-2018-318802)
Pickrell, W. O. and Robertson, N. P. 2018. New treatments in Alzheimer's disease. Journal of Neurology 265(9), pp. 2162-2163. (10.1007/s00415-018-9018-1)
Pariani, N. et al. 2018. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. Journal of Clinical Endocrinology & Metabolism 108(8), pp. 3010-3018. (10.1210/jc.2018-00359)
Willis, M. D. and Robertson, N. P. 2018. Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease. Journal of Neurology 265(8), pp. 1950-1952. (10.1007/s00415-018-8963-z)
Loveless, S. et al. 2018. Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis. Brain Pathology 28(4), pp. 507-520. (10.1111/bpa.12546)
Hu, M. and Robertson, N. P. 2018. Transmissible amyloid protein: evidence from iatrogenic CJD. Journal of Neurology 265(7), pp. 1726-1729. (10.1007/s00415-018-8927-3)
Castle, D. and Robertson, N. P. 2018. Monoclonal antibodies for migraine: an update. Journal of Neurology 265(6), pp. 1491-1492. (10.1007/s00415-018-8886-8)
Alsaeed, M. et al. 2018. Multiple sclerosis: long-term outcomes in ethnic minorities. analysis of a UK population-based registry. European Journal of Neurology 25(4), pp. 701-704. (10.1111/ene.13571)
McLauchlan, D. and Robertson, N. P. 2018. Stem cells in the treatment of central nervous system disease. Journal of Neurology 265(4), pp. 984-986. (10.1007/s00415-018-8818-7)
Tallantyre, E., Whittam, D. H., Jolles, S., Paling, D., Constantinescu, C., Robertson, N. and Jacob, A. 2018. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. Journal of Neurology 265(5), pp. 1115-1122. (10.1007/s00415-018-8812-0)
Massey, T. and Robertson, N. 2018. Repurposing drugs to treat neurological diseases. Journal of Neurology 265(2), pp. 446-448. (10.1007/s00415-018-8732-z)
Edwards, M. and Robertson, N. 2018. Seizures in Alzheimer's disease: is there more beneath the surface?. Journal of Neurology 265(1), pp. 226-228. (10.1007/s00415-017-8694-6)

2017

Pickrell, W. O. and Robertson, N. P. 2017. Cannabidiol as a treatment for epilepsy. Journal of Neurology 264(12), pp. 2506-2508. (10.1007/s00415-017-8663-0)
Harding, K. and Robertson, N. 2017. Epidemiology of progressive multiple sclerosis. In: Wilkins, A. ed. Progressive Multiple Sclerosis. Springer, pp. 31-47., (10.1007/978-3-319-65921-3_2)
Wynford-Thomas, R. and Robertson, N. 2017. The economic burden of chronic neurological disease. Journal of Neurology 264(11), pp. 2345-2347. (10.1007/s00415-017-8632-7)
McLauchlan, D., Malik, G. A. and Robertson, N. P. 2017. Cerebral amyloid angiopathy: subtypes, treatment and role in cognitive impairment. Journal of Neurology 264, pp. 2184-2186. (10.1007/s00415-017-8608-7)
Welton, J. L., Loveless, S., Stone, T., Von Ruhland, C., Robertson, N. and Clayton, A. 2017. Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis. Journal of Extracellular Vesicles 6(1), article number: 1369805. (10.1080/20013078.2017.1369805)
Hrastelj, J. and Robertson, N. 2017. Genetics of disease severity in multiple sclerosis, Alzheimer's disease, and Huntington's disease: rejuvenating genome-wide association studies. Journal of Neurology 264(9), pp. 2040-2042. (10.1007/s00415-017-8584-y)
Crawshaw, A. A. and Robertson, N. P. 2017. The role of TSPO PET in assessing neuroinflammation. Journal of Neurology 264(8), pp. 1825-1827. (10.1007/s00415-017-8565-1)
Massey, T. and Robertson, N. 2017. Why antisense could make sense for neurodegeneration. Journal of Neurology 264(7), pp. 1542-1544. (10.1007/s00415-017-8515-y)
Hakobyan, S., Luppe, S., Evans, D. R. S., Harding, K., Loveless, S., Robertson, N. P. and Morgan, B. P. 2017. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal 23(7), pp. 946-955., article number: 135245851666900. (10.1177/1352458516669002)
Harding, K. et al. 2017. Seasonal variation in multiple sclerosis relapse. Journal of Neurology 264(6), pp. 1059-1067. (10.1007/s00415-017-8485-0)
Willis, M. D. and Robertson, N. P. 2017. Chronic traumatic encephalopathy: identifying those at risk and understanding pathogenesis. Journal of Neurology 264(6), pp. 1298-1300. (10.1007/s00415-017-8508-x)
Al-Ansari, A. and Robertson, N. 2017. Creutzfeldt-Jacob disease: new directions in diagnosis and therapeutics. Journal of Neurology 264(5), pp. 1029-1031. (10.1007/s00415-017-8473-4)
Absoud, M. et al. 2017. A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). Health Technology Assessment 21, article number: 31. (10.3310/hta21310)
Kalincik, T. et al. 2017. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology 16(4), pp. 271-281. (10.1016/S1474-4422(17)30007-8)
Willis, M. et al. 2017. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neuroimmunology and Neuroinflammation 4(2), article number: E320. (10.1212/NXI.0000000000000320)
Robertson, N. and Peall, K. J. 2017. Dystonia: opportunities to gain insights into underlying pathophysiological mechanisms. Journal of Neurology 264(3), pp. 616-618. (10.1007/s00415-017-8411-5)
McLauchlan, D. and Robertson, N. P. 2017. B cell treatments for multiple sclerosis. Journal of Neurology 264(4), pp. 814-816. (10.1007/s00415-017-8442-y)
Marouli, E. et al. 2017. Rare and low-frequency coding variants alter human adult height. Nature 542, pp. 186-190. (10.1038/nature21039)
Malik, G. A. and Robertson, N. P. 2017. Treatments in Alzheimer's disease. Journal of Neurology 264(2), pp. 416-418. (10.1007/s00415-017-8395-1)
Jones, L. and Robertson, N. 2017. An update on treatments in myasthenia gravis. Journal of Neurology 264(1), pp. 205-207. (10.1007/s00415-016-8359-x)

2016

Thomas, R. H. and Robertson, N. 2016. What can rare variant genetics tell us about cognition and intellectual difficulties?. Journal of Neurology 263(12), pp. 2565-2566. (10.1007/s00415-016-8326-6)
Tilling, K. et al. 2016. Modelling disease progression in relapsing?remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. Health Technology Assessment 20(81) (10.3310/hta20810)
Clement, M. et al. 2016. Targeted suppression of autoreactive CD8+ T-cell activation using blocking anti-CD8 antibodies. Scientific Reports 6, article number: 35332. (10.1038/srep35332)
Hrastelj, J. and Robertson, N. 2016. Ice bucket challenge bears fruit for amyotrophic lateral sclerosis. Journal of Neurology 263(11), article number: 2355. (10.1007/s00415-016-8297-7)
Willis, M., Pickersgill, T., Robertson, N., Lee, R. W. J., Dick, A. D. and Carreño, E. 2016. Alemtuzumab-induced remission of multiple sclerosis-associated uveitis. International Ophthalmology (10.1007/s10792-016-0370-9)
Pickrell, W. O. and Robertson, N. 2016. Stem cell treatment for multiple sclerosis. Journal of Neurology 263(10), pp. 2145-2147. (10.1007/s00415-016-8284-z)
Davies, F. et al. 2016. The transition to secondary progressive multiple sclerosis: an exploratory qualitative study of health professionals' experiences. International Journal of MS Care 18(5), pp. 257-264. (10.7224/1537-2073.2015-062)
Thomas, R. H. and Robertson, N. 2016. The consequences of valproate exposure in utero. Journal of Neurology 263(9), pp. 1887-1889. (10.1007/s00415-016-8269-y)
Willis, M. and Robertson, N. 2016. Alemtuzumab for multiple sclerosis. Current Neurology and Neuroscience Reports 16, article number: 84. (10.1007/s11910-016-0685-y)
Rodríguez Cruz, P. M. et al. 2016. Time and region-specific season of birth effects in multiple sclerosis in the United Kingdom. JAMA Neurology 73(8), pp. 954-960. (10.1001/jamaneurol.2016.1463)
Willis, M. et al. 2016. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Multiple Sclerosis Journal 22(9), pp. 1215-1223., article number: 1352458515614092. (10.1177/1352458515614092)
Peall, K. J. and Robertson, N. 2016. Idiopathic rapid eye movement sleep behaviour disorder: a potential gateway to the development of disease-modifying treatments in neurodegenerative disorders. Journal of Neurology 263(8), pp. 1678-1680. (10.1007/s00415-016-8235-8)
Watkins, L. M. et al. 2016. Complement is activated in progressive multiple sclerosis cortical grey matter lesions. Journal of Neuroinflammation 13, article number: 161. (10.1186/s12974-016-0611-x)
McLauchlan, D. J. and Robertson, N. 2016. Reversing the trend: interventions to treat intracranial haemorrhage associated with anticoagulation. Journal of Neurology 263(7), pp. 1468-1470. (10.1007/s00415-016-8198-9)
Massey, T. and Robertson, N. 2016. Zika virus and neurology: proving cause and effect. Journal of Neurology 263(6), pp. 1255-1257. (10.1007/s00415-016-8165-5)
Harding, K. and Robertson, N. 2016. Deep brain stimulation for dystonia. Journal of Neurology 263(5), pp. 1045-1046. (10.1007/s00415-016-8137-9)
Tallantyre, E. C. and Robertson, N. P. 2016. Continuous evolution of magnetic resonance imaging in multiple sclerosis. Journal of Neurology 263(4), pp. 835-837. (10.1007/s00415-016-8099-y)
Butterworth, S. E., Ingram, G. and Robertson, N. 2016. Advances in biomarker research in multiple sclerosis [Journal Club]. Journal of Neurology 263(3), pp. 621-623. (10.1007/s00415-016-8062-y)
Mitchell, C. J. and Robertson, N. 2016. New ways of looking at an old disease: the reimagination of epilepsy. Journal of Neurology 263(2), pp. 414-416. (10.1007/s00415-016-8025-3)
Tallantyre, E. C., Wardle, M. and Robertson, N. 2016. How to run a multiple sclerosis relapse clinic. Practical Neurology 16(1), pp. 62-69. (10.1136/practneurol-2015-001214)
Cauchi, M. and Robertson, N. 2016. CGRP and migraine. Journal of Neurology 263(1), pp. 192-194. (10.1007/s00415-015-8000-4)

2015

Wynford-Thomas, R. and Robertson, N. 2015. The role of skin biopsy in differentiating idiopathic Parkinson's disease from other types of parkinsonism. Journal of Neurology 262(12), pp. 2793-2795. (10.1007/s00415-015-7974-2)
Lawton, M. et al. 2015. A longitudinal model for disease progression was developed and applied to multiple sclerosis. Journal of Clinical Epidemiology 68(11), pp. 1355-1365. (10.1016/j.jclinepi.2015.05.003)
Healy, S., Willis, M. and Robertson, N. P. 2015. Prognosis in multiple sclerosis and the unveiling of pathogenic clues. Journal of Neurology 262(11), pp. 2596-2598. (10.1007/s00415-015-7938-6)
McLauchlan, D. J. and Robertson, N. 2015. Refining the phenotype of inborn errors of metabolism. Journal of Neurology 262(10), pp. 2396-2398. (10.1007/s00415-015-7917-y)
Peall, K. J. and Robertson, N. 2015. Biomarkers in Alzheimer's Disease: understanding disease trajectory and therapeutic targets. Journal of Neurology 262(9), pp. 2195-2197. (10.1007/s00415-015-7881-6)
Thomas, R. H. and Robertson, N. 2015. Testing new treatments for paediatric epilepsies. Journal of Neurology 262(8), pp. 1996-1998. (10.1007/s00415-015-7857-6)
Davies, F. et al. 2015. "You are just left to get on with it": qualitative study of patient and carer experiences of the transition to secondary progressive multiple sclerosis. BMJ Open 5(7), article number: e007674. (10.1136/bmjopen-2015-007674)
Hrastelj, J. and Robertson, N. 2015. Improving survival in amyotrophic lateral sclerosis: future treatments in a modern service. Journal of Neurology 262(7), pp. 1791-1793. (10.1007/s00415-015-7811-7)
Harding, K. and Robertson, N. 2015. HIV-associated neurocognitive disorders. Journal of Neurology 262(6), pp. 1596-1598. (10.1007/s00415-015-7783-7)
Absoud, M. et al. 2015. Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). BMJ Open 5(5), article number: e008312. (10.1136/bmjopen-2015-008312)
Palace, J. et al. 2015. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurology 14(5), pp. 497-505. (10.1016/S1474-4422(15)00018-6)
Williams, O., Tallantyre, E. C. and Robertson, N. 2015. Traumatic brain injury: pathophysiology, clinical outcome and treatment. Journal of Neurology 262(5), pp. 1394-1396. (10.1007/s00415-015-7741-4)
Ingram, G. and Robertson, N. P. 2015. Pathophysiology of neuropsychiatric disorders: moving forward. Journal of Neurology 262(4), pp. 1096-1098. (10.1007/s00415-015-7706-7)
Willis, M., Harding, K., Wardle, M., Pickersgill, T. P., Tomassini, V., Loveless, S. and Robertson, N. 2015. Site-specific clinical disease onset in multiple sclerosis. European Journal of Neurology 22(4), pp. 732-735. (10.1111/ene.12564)
Willis, M. and Robertson, N. 2015. Alemtuzumab for the treatment of multiple sclerosis. Therapeutics and Clinical Risk Management 2015(11), pp. 525-534. (10.2147/TCRM.S80112)
Amin, R. and Robertson, N. 2015. Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. Journal of Neurology 262(3), pp. 789-791. (10.1007/s00415-015-7667-x)
Fung, W. and Robertson, N. 2015. Natalizumab in MS: JC antibody index. Journal of Neurology 262(2), pp. 492-494. (10.1007/s00415-015-7641-7)
Harding, K. . E., Wardle, M., Moore, P., Tomassini, V., Pickersgill, T., Ben-Shlomo, Y. and Robertson, N. P. 2015. Modelling the natural history of primary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 86, pp. 13-19. (10.1136/jnnp-2014-307791)
Tallantyre, E., Causon, E. G., Harding, K., Pickersgill, T. P. and Robertson, N. 2015. The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic. Multiple Sclerosis Journal 21(1), pp. 67-75. (10.1177/1352458514538333)
Tallantyre, E. C. and Robertson, N. 2015. Acute stroke management. Journal of Neurology 262(1), pp. 239-242. (10.1007/s00415-014-7607-1)
Tuohy, O. et al. 2015. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. Journal of Neurology, Neurosurgery & Psychiatry 86(2), pp. 208-215. (10.1136/jnnp-2014-307721)

2014

Malik, G. and Robertson, N. 2014. Functional neurology: new directions in causes, prognosis and treatment. Journal of Neurology 261(12), pp. 2463-2465. (10.1007/s00415-014-7573-7)
Ingram, G. and Robertson, N. 2014. Accurate diagnosis of inflammatory neuropathies. Journal of Neurology 261(11), pp. 2244-2246. (10.1007/s00415-014-7531-4)
Elsone, L. et al. 2014. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Multiple Sclerosis Journal 20(11), pp. 1533-1540. (10.1177/1352458514525870)
Thomas, R. H. and Robertson, N. 2014. Novel auto-antibody syndromes. Journal of Neurology 261(10), pp. 2043-2045. (10.1007/s00415-014-7497-2)
Willis, M., Harding, K., Wardle, M., Pickersgill, T., Tomassini, V. and Robertson, N. 2014. Alemtuzumab: Long term follow-up in a single centre cohort. Journal of Neurology, Neurosurgery & Psychiatry 85(10), pp. A1-A57. (10.1136/jnnp-2014-309236.8)
Ingram, G. et al. 2014. Complement activation in MS: An immunohistochemical analysis. Journal of Neurology, Neurosurgery & Psychiatry 85(10), pp. e4.13. (10.1136/jnnp-2014-309236.11)
Harding, K., Willis, M., Wardle, M., Pickersgill, T. and Robertson, N. 2014. No temporal effect on disability in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 85(10), pp. e4.2. (10.1136/jnnp-2014-309236.10)
McLauchlan, D. and Robertson, N. 2014. Reducing central nervous system complications associated with the human immunodeficiency virus. Journal of Neurology 261(9), pp. 1842-1845. (10.1007/s00415-014-7466-9)
Peall, K. J. and Robertson, N. 2014. Narcolepsy: environment, genes and treatment. Journal of Neurology 261(8), pp. 1644-1646. (10.1007/s00415-014-7435-3)
Willis, M. and Robertson, N. 2014. Drug safety evaluation of alemtuzumab for multiple sclerosis. Expert Opinion on Drug Safety 13(8), pp. 1115-1124. (10.1517/14740338.2014.928691)
Azzopardi, L. et al. 2014. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 85(7), pp. 795-98. (10.1136/jnnp-2013-307042)
Willis, M. and Robertson, N. 2014. Treatment paradigms in multiple sclerosis: who, when and how to treat?. Journal of Neurology 261(7), pp. 1444-1446. (10.1007/s00415-014-7420-x)
Palace, J. and Robertson, N. 2014. Modifying disability in progressive multiple sclerosis. Lancet 383(9936), pp. 2189-2191. (10.1016/S0140-6736(13)62641-0)
Robertson, N. and Scolding, N. J. 2014. Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab. Neurology 82(24), pp. 2150-2215. (10.1212/WNL.0000000000000530)
Harding, K. and Robertson, N. 2014. Applications of next-generation whole exome sequencing. Journal of Neurology 261(6), pp. 1244-1246. (10.1007/s00415-014-7372-1)
Ingram, G. et al. 2014. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathologica Communications 2, article number: 53. (10.1186/2051-5960-2-53)
Ali, K. and Robertson, N. 2014. Evolving concepts in migraine. Journal of Neurology 261(5), pp. 1046-1048. (10.1007/s00415-014-7348-1)
Aguirregomozcorta, M. and Robertson, N. 2014. Pregnancy and drug use in neurological disease. Journal of Neurology 261(4), pp. 842-844. (10.1007/s00415-014-7312-0)
Luppe, S. and Robertson, N. 2014. MOG-IgG in neuromyelitis optica. Journal of Neurology 261(3), pp. 640-642. (10.1007/s00415-014-7277-z)
Flower, M. D. and Robertson, N. 2014. POLG: a cause of intractable epilepsy. Journal of Neurology 261(2), pp. 446-448. (10.1007/s00415-014-7255-5)
Amin, R. A. and Robertson, N. 2014. Risk and sub phenotype in Parkinson's disease. Journal of Neurology 261(1), pp. 245-7. (10.1007/s00415-013-7214-6)
Stewart, J. P. et al. 2014. Seroprevalence of molluscum contagiosum virus in German and UK populations. PLoS ONE 9(2), article number: e88734. (10.1371/journal.pone.0088734)

2013

Pryce-Roberts, A. and Robertson, N. 2013. Possible treatment targets in Alzheimer's disease. Journal of Neurology 260(12), pp. 3193-6. (10.1007/s00415-013-7195-5)
McLauchlan, D. and Robertson, N. 2013. Epigenetics of Huntington's disease. Journal of Neurology 260(11), pp. 2938-41. (10.1007/s00415-013-7158-x)
Beecham, A. H. et al. 2013. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics 45(11), pp. 1353-60. (10.1038/ng.2770)
Harding, K. and Robertson, N. 2013. Traumatic brain injury: risk factors and prognostic assessment. Journal of Neurology 260(10), pp. 2691-3. (10.1007/s00415-013-7106-9)
Hubers, A. A. et al. 2013. Suicidal ideation in a European Huntington's disease population. Journal of Affective Disorders 151(1), pp. 248-58. (10.1016/j.jad.2013.06.001)
Moore, P., Harding, K., Clarkson, H., Pickersgill, T., Wardle, M. and Robertson, N. 2013. Demographic and clinical factors associated with changes in employment in multiple sclerosis. Multiple Sclerosis Journal 19(12), pp. 1647-1654. (10.1177/1352458513481396)
Willis, M. and Robertson, N. 2013. Amyotrophic lateral sclerosis: new hope for an old disease?. Journal of Neurology 260(9), pp. 2441-3. (10.1007/s00415-013-7063-3)
Ali, K. W. and Robertson, N. 2013. Lessons from preclinical disease. Journal of Neurology 260(8), pp. 2193-5. (10.1007/s00415-013-7055-3)
McLauchlan, D. and Robertson, N. 2013. Epidemiological aspects of Guillain-Barre syndrome. Journal of Neurology 260(7), pp. 1942-5. (10.1007/s00415-013-7009-9)
Harding, K. and Robertson, N. 2013. Assessment of long-term outcome in neurological disease. Journal of Neurology 260(6), pp. 1693-5. (10.1007/s00415-013-6966-3)
Kronenberg, F. et al. 2013. Novel Loci Associated with Increased Risk of Sudden Cardiac Death in the Context of Coronary Artery Disease [Article]. PLoS ONE 8(4), pp. e59905. (10.1371/journal.pone.0059905)
Matthews, L. et al. 2013. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution [Article]. Neurology 80(14), pp. 1330-1337. (10.1212/WNL.0b013e3182887957)
Tallantyre, E. C. and Robertson, N. 2013. Autism and intellectual disability. Journal of Neurology 260(3), pp. 936-939. (10.1007/s00415-013-6861-y)
Anderson, J. T. and Robertson, N. 2013. Risk factors and cerebrovascular disease [Journal Article]. Journal of Neurology 260(2), pp. 692-694. (10.1007/s00415-013-6835-0)
Cossburn, M. D. et al. 2013. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 80(1), pp. 55-61. (10.1212/WNL.0b013e31827b5927)
Harding, K. et al. 2013. Long-term outcome of paediatric-onset multiple sclerosis: a population-based study. Journal of Neurology, Neurosurgery & Psychiatry 84(2), pp. 141-147. (10.1136/jnnp-2012-303996)
Peall, K. J. and Robertson, N. 2013. Parkinsonism, dementia and glucocerebrosidase mutations. Journal of Neurology 260(5), pp. 1441-1444. (10.1007/s00415-013-6923-1)
Ingram, G. and Robertson, N. 2013. Antibody mediated encephalitis [Journal Article]. Journal of Neurology 260(4), pp. 1187-1190. (10.1007/s00415-013-6890-6)

2012

Cooper, J. D. et al. 2012. Seven newly identified loci for autoimmune thyroid disease. Human Molecular Genetics 21(23), pp. 5202-5208. (10.1093/hmg/dds357)
Jostins, L. et al. 2012. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491(7422), pp. 119-124. (10.1038/nature11582)
Willis, M. and Robertson, N. 2012. Aphasia: early classification, evaluation of existing therapy, and novel therapeutics. Journal of Neurology 259(11), pp. 2510-2512. (10.1007/s00415-012-6701-5)
McLauchlan, D. J. and Robertson, N. 2012. Management of status epilepticus. Journal of Neurology 259(10), pp. 2261-2263. (10.1007/s00415-012-6673-5)
Moore, P., Hirst, C. L., Harding, K., Clarkson, H., Pickersgill, T. and Robertson, N. 2012. Multiple sclerosis relapses and depression. Journal of Psychosomatic Research 73(4), pp. 272-276. (10.1016/j.jpsychores.2012.08.004)
Ingram, G. et al. 2012. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Multiple Sclerosis Journal 18(10), pp. 1401-1411. (10.1177/1352458512438238)
Kendall, K. and Robertson, N. 2012. Neuroimaging. Journal of Neurology 259(9), pp. 2009-2011. (10.1007/s00415-012-6652-x)
Harding, K., Ingram, G., Cossburn, M. D., Hirst, C. L., Pickersgill, T., Ben-Shlomo, Y. and Robertson, N. 2012. Genotype-phenotype correlation for non-HLA disease associated risk alleles in multiple sclerosis. Neuroscience Letters 526(1), pp. 15-19. (10.1016/j.neulet.2012.06.040)
Harding, K. and Robertson, N. 2012. The interaction between acquired mitochondrial disease and neurodegeneration. Journal of Neurology 259(8), pp. 1761-1763. (10.1007/s00415-012-6614-3)
Hirst, C. L., Ingram, G., Pickersgill, T. P. and Robertson, N. 2012. Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome. Multiple Sclerosis Journal 18(8), pp. 1152-1158. (10.1177/1352458511433919)
Harding, K. and Robertson, N. 2012. Understanding mechanisms and treatments for neuropathic disease. Journal of Neurology 259(7), pp. 1509-1511. (10.1007/s00415-012-6587-2)
Hirst, C. L. and Robertson, N. 2012. There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion - No. Multiple Sclerosis Journal 18(7), pp. 925-926. (10.1177/1352458512450089)
Harding, K. and Robertson, N. 2012. Stem cells: from animal models to clinical practice. Journal of Neurology 259(6), pp. 1257-1259. (10.1007/s00415-012-6555-x)
Robertson, N. 2012. New and old: notable drug developments for clinical practice. Journal of Neurology 259(5), pp. 1003-1005. (10.1007/s00415-012-6518-2)
Robertson, N. 2012. The C9ORF72 syndrome: implications for clinical practice. Journal of Neurology 259(4), pp. 794-796. (10.1007/s00415-012-6479-5)
Becker, E. B. E. et al. 2012. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. Journal of Neurology, Neurosurgery & Psychiatry 83(4), pp. 437-440. (10.1136/jnnp-2011-301506)
Cossburn, M. et al. 2012. The prevalence of neuromyelitis optica in South East Wales. European Journal of Neurology 19(4), pp. 655-659. (10.1111/j.1468-1331.2011.03529.x)
Kendall, K., Thomas, R., Corkill, R. G. and Robertson, N. 2012. A neurological presentation of intravascular B-cell lymphoma. Case Reports (10.1136/bcr-2012-006439)
Kendall, K., Thomas, R. H., Lammie, G. A., Neal, J. W., Corkill, R. G. and Robertson, N. 2012. 176 Intravascular B cell lymphoma: a case series [Conference Abstract]. Journal of Neurology, Neurosurgery & Psychiatry 83(3), pp. e1-e1. (10.1136/jnnp-2011-301993.218)

2011

Ingram, G., Hakobyan, S., Loveless, S., Robertson, N. and Morgan, B. P. 2011. Complement regulator factor H in multiple sclerosis. Journal of Cellular Biochemistry 112(10), pp. 2653-2654. (10.1002/jcb.23204)
Cossburn, M. D. et al. 2011. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77(6), pp. 573-579. (10.1212/WNL.0b013e318228bec5)
Robertson, N. and The International Multiple Sclerosis Genetics Consortium, . 2011. The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: A multicenter case-control study. PLoS ONE 6(4), article number: e18813. (10.1371/journal.pone.0018813)
Wickremaratchi, M. M. et al. 2011. The motor phenotype of Parkinson's disease in relation to age at onset. Movement Disorders 26(3), pp. 457-463. (10.1002/mds.23469)
Sawcer, S. et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476(7359), pp. 214-219. (10.1038/nature10251)
Cossburn, M. D., Ingram, G., Hirst, C. L., Ben-Shlomo, Y., Pickersgill, T. and Robertson, N. 2011. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Multiple Sclerosis Journal 18(1), pp. 45-54. (10.1177/1352458511417479)
Bennetto, L., Burrow, J., Sakai, H., Cobby, J., Robertson, N. and Scolding, N. 2011. The relationship between relapse, impairment and disability in multiple sclerosis. Multiple Sclerosis Journal 17(10), pp. 1218-1224. (10.1177/1352458511407368)

2010

Ingram, G., Hirst, C. L., Robertson, N., Rolak, L. A. and Bejaoui, K. 2010. What is the risk of permanent disability from a multiple sclerosis relapse? [Letter]. Neurology 75(9), pp. 837. (10.1212/WNL.0b013e3181eeea87)
Ingram, G. et al. 2010. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133(6), pp. 1602-1611. (10.1093/brain/awq085)
Ingram, G., Colley, E., Ben-Shlomo, Y., Cossburn, M. D., Hirst, C. L., Pickersgill, T. and Robertson, N. 2010. Validity of patient-derived disability and clinical data in multiple sclerosis. Multiple Sclerosis Journal 16(4), pp. 472-479. (10.1177/1352458509358902)
Booth, D. R. et al. 2010. Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis [Letter]. Nature Genetics 42(6), pp. 469-470. (10.1038/ng0610-469)
Marsh, E. A. et al. 2010. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. Journal of Neurology 257(6), pp. 913-919. (10.1007/s00415-009-5437-3)
Ingram, G., Hakobyan, S., Robertson, N. and Morgan, B. P. 2010. Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. Journal of Neuroimmunology 223(1-2), pp. 124-127. (10.1016/j.jneuroim.2010.03.014)
Ingram, G., Bugert, J. J., Loveless, S. and Robertson, N. 2010. Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. European Journal of Neurology 17(11), pp. 1386-1389. (10.1111/j.1468-1331.2010.03083.x)
Ingram, G. and Robertson, N. 2010. The association between Anti-EBNA-1 IgG and multiple sclerosis clinical disease activity - response. European Journal of Neurology 17(10), pp. e96. (10.1111/j.1468-1331.2010.03159.x)
Ban, M. et al. 2010. A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis. Genes and Immunity 11(8), pp. 660-664. (10.1038/gene.2010.36)
Booth, D. R. et al. 2010. IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes and Immunity 11(5), pp. 397-405. (10.1038/gene.2010.28)

2009

Wardle, M., Morris, H. R. and Robertson, N. 2009. Clinical and genetic characteristics of non-Asian dentatorubral-pallidoluysian atrophy: a systematic review. Movement Disorders 24(11), pp. 1636-1640. (10.1002/mds.22642)
Wickremaratchi, M. M. et al. 2009. Prevalence and age of onset of Parkinson's disease in Cardiff: A community based cross sectional study and meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry 80(7), pp. 805-807. (10.1136/jnnp.2008.162222)
Wardle, M., Muzaimi, M. B. and Robertson, N. 2009. Late onset cerebellar ataxia: Natural history and prognosis [Abstract]. Journal of Neurology Neurosurgery and Psychiatry 80(1), pp. 106-106.
Wardle, M., Majounie, E., Muzaimi, M. B., Williams, N. M., Morris, H. R. and Robertson, N. 2009. The genetic aetiology of late-onset chronic progressive cerebellar ataxia. Journal of Neurology 256(3), pp. 343-348. (10.1007/s00415-009-0015-2)
Ingram, G., Hakobyan, S., Robertson, N. and Morgan, B. P. 2009. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clinical and Experimental Immunology 155(2), pp. 128-139. (10.1111/j.1365-2249.2008.03830.x)
Hirst, C. L., Ingram, G., Pickersgill, T., Swingler, R., Compston, D. A. S. and Robertson, N. 2009. Increasing prevalence and incidence of multiple sclerosis in South East Wales. Journal of Neurology, Neurosurgery & Psychiatry 80(4), pp. 386-391. (10.1136/jnnp.2008.144667)
Joseph, F. G., Hirst, C. L., Pickersgill, T., Ben-Shlomo, Y., Robertson, N. and Scolding, N. J. 2009. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. Journal of Neurology, Neurosurgery & Psychiatry 80(3), pp. 292-296. (10.1136/jnnp.2008.150896)
Booth, D. R. et al. 2009. The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes and Immunity 10(1), pp. 11-14. (10.1038/gene.2008.83)
Wilkins, A., Ingram, G., Brown, A., Jardine, P., Steward, C. G., Robertson, N. and Scolding, N. J. 2009. Very long chain fatty acid levels in patients diagnosed with multiple sclerosis. Multiple Sclerosis Journal 15(12), pp. 1525-1527. (10.1177/1352458509351731)
Ban, M. et al. 2009. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. European Journal of Human Genetics 17(10), pp. 1309-1313. (10.1038/ejhg.2009.41)
De Silva, R. et al. 2009. Management of ataxias: guidelines on best clinical practice. London: Ataxia.org.uk.

2008

Hafler, J. P. et al. 2008. CD226 Gly307Ser association with multiple autoimmune diseases. Genes and Immunity 10(1), pp. 5-10. (10.1038/gene.2008.82)
Hirst, C. L., Ingram, G., Swingler, R., Compston, D. A. S., Pickersgill, T. and Robertson, N. 2008. Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis. Journal of Neurology, Neurosurgery and Psychiatry 79(10), pp. 1137-1143. (10.1136/jnnp.2007.133785)
Segal, B. M., Constantinescu, C. S., Raychaudhuri, A., Kim, L., Fidelus-Gort, R., Kasper, L. H. and Robertson, N. 2008. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. The Lancet Neurology 7(9), pp. 796-804. (10.1016/S1474-4422(08)70173-X)
Hirst, C. L. et al. 2008. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. Journal of Neurology 255(2), pp. 231-238. (10.1007/s00415-008-0696-y)
Wardle, M., Majounie, E., Williams, N. M., Rosser, A. E., Morris, H. R. and Robertson, N. 2008. Dentatorubral pallidoluysian atrophy in South Wales. Journal of Neurology, Neurosurgery and Psychiatry 79(7), pp. 804-807. (10.1136/jnnp.2007.128074)
, . and , . 2008. Refining genetic associations in multiple sclerosis. Lancet Neurology 7(7), pp. 567-569. (10.1016/S1474-4422(08)70122-4)
Hirst, C. L., Ingram, G., Pearson, O. R., Pickersgill, T., Scolding, N. and Robertson, N. 2008. Contribution of relapses to disability in multiple sclerosis. Journal of Neurology 255(2), pp. 280-287. (10.1007/s00415-008-0743-8)
Hirst, C. L., Swingler, R., Compston, D. A. S., Ben-Shlomo, Y. and Robertson, N. 2008. Survival and cause of death in multiple sclerosis: a prospective population-based study. Journal of Neurology, Neurosurgery & Psychiatry 79(9), pp. 1016-1021. (10.1136/jnnp.2007.127332)

2007

Majounie, E., Wardle, M., Muzaimi, M., Cross, W. C., Robertson, N., Williams, N. M. and Morris, H. R. 2007. Case control analysis of repeat expansion size in ataxia. Neuroscience Letters 429(1), pp. 28-32. (10.1016/j.neulet.2007.09.055)
Wiles, C. et al. 2007. Clinical skills evaluation of trainees in a neurology department. Clinical Medicine 7(4), pp. 365-369. (10.7861/clinmedicine.7-4-365)
Wardle, M. and Robertson, N. 2007. Chronic progressive late onset cerebellar ataxia [Review]. Advances in Clinical Neuroscience and Rehabilitation 7(2), pp. 6-12.
De Silva, R. et al. 2007. Management of ataxias: guidelines on best clinical practice. London: Ataxia.org.uk.

2006

Hirst, C., Robertson, N., Llewelyn, G., Hirst, C. and Raasch, S. 2006. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). Journal of Neurology, Neurosurgery & Psychiatry 77(6), pp. 800-802. (10.1136/jnnp.2005.076869)

2005

Pearson, O. R., Busse, M., Robertson, N., Van Deursen, R. W. M. and Wiles, C. M. 2005. Can actual real-life mobility be measured? (Abstract). Journal of the Neurological Sciences 238(S1), pp. S347-S348.

2004

Muzaimi, M. B. et al. 2004. Population based study of late onset cerebellar ataxia in south east Wales. Journal of Neurology, Neurosurgery and Psychiatry 75(8), pp. 1129-1134. (10.1136/jnnp.2003.014662)

2003

Zajicek, J. et al. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. The Lancet 362(9395), pp. 1517-1526. (10.1016/S0140-6736(03)14738-1)
Muzaimi, M. B., Wiles, C. M., Robertson, N., Ravine, D. and Compston, D. 2003. Task specific focal dystonia: a presentation of spinocerebellar ataxia type 6. Journal of Neurology, Neurosurgery & Psychiatry 74(10), pp. 1444-1445. (10.1136/jnnp.74.10.1444)
Vincent, A., Clover, L., Buckley, C., Grimley Evans, J., Rothwell, P., UK Myasthenia Gravis Survey, . and Robertson, N. 2003. Evidence of underdiagnosis of myasthenia gravis in older people. Journal of Neurology, Neurosurgery & Psychiatry 74(8), pp. 1105-1108. (10.1136/jnnp.74.8.1105)

2001

Chataway, J. et al. 2001. Multiple sclerosis in sibling pairs: an analysis of 250 families. Journal of Neurology, Neurosurgery and Psychiatry 71(6), pp. 757-761. (10.1136/jnnp.71.6.757)
Hillier, C. and Robertson, N. 2001. Practical management of headache in primary care medicine. British Journal of Hospital Medicine 62(11), pp. 634-641.
Hupperts, R., Broadley, S., Mander, A., Clayton, D., Compston, D. A. and Robertson, N. P. 2001. Patterns of disease in concordant parent-child pairs with multiple sclerosis. Neurology 57(2), pp. 290-295.

2000

Robertson, N. 2000. Enumerating neurology. Brain 123(4), pp. 663-664. (10.1093/brain/123.4.663)

1999

Hennessey, A., Robertson, N., Swingler, R. and Compston, D. A. 1999. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. Journal of Neurology 246(11), pp. 1027-1032. (10.1007/s004150050508)
McNamara, B., Boniface, S. J., Ray, J., Scolding, N. J. and Robertson, N. 1999. Paraneoplastic sensory neuropathy and Purkinje cell antibodies [Letter]. Muscle & Nerve 22(10), pp. 1466-1467. (10.1002/(SICI)1097-4598(199910)22:10<1466::AID-MUS20>3.0.CO;2-D)
Robertson, N. 1999. An Atlas of Multiple Sclerosis [Book Review]. Journal of Neurology, Neurosurgery & Psychiatry 67(1), pp. 132-132. (10.1136/jnnp.67.1.132a)
Robertson, N., Compston, D. A. and Kirkpatrick, P. 1999. Moyamoya disease presenting as Valsalva related partial seizures. Journal of Neurology, Neurosurgery & Psychiatry 66(1), pp. 111. (10.1136/jnnp.66.1.111)

1998

Robertson, N. P., Wharton, S., Anderson, J. and Scolding, N. J. 1998. Adult polyglucosan body disease associated with an extrapyramidal syndrome. Journal of Neurology, Neurosurgery & Psychiatry 65(5), pp. 788-790. (10.1136/jnnp.65.5.788)
Robertson, N., Deans, J. and Compston, D. A. 1998. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. Journal of Neurology, Neurosurgery & Psychiatry 65(4), pp. 492-496. (10.1136/jnnp.65.4.492)
Chataway, J. et al. 1998. The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen. Brain 121(10), pp. 1869-1887. (10.1093/brain/121.10.1869)
Robertson, N., Shaunak, S. and Compston, D. A. 1998. Urgent neurology out-patient referrals from primary health care physicians. QJM: An International Journal of Medicine 91(4), pp. 309-313. (10.1093/qjmed/91.4.309)

1997

Robertson, N., O'Riordan, J. I., Chataway, J., Kingsley, D. P., Miller, D. H., Clayton, D. and Compston, D. A. 1997. Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. The Lancet 349(9065), pp. 1587-1590. (10.1016/S0140-6736(96)07317-5)

1996

Chalmers, R. M., Robertson, N., Compston, D. A. S. and Harding, A. E. 1996. Sequence of mitochondrial DNA in patients with multiple sclerosis. Annals of Neurology 40(2), pp. 239-243. (10.1002/ana.410400216)
Robertson, N., Clayton, D., Fraser, M., Deans, J. and Compston, D. A. 1996. Clinical concordance in sibling pairs with multiple sclerosis. Neurology 47(2), pp. 347-352. (10.1212/WNL.47.2.347)
Sawcer, S. et al. 1996. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nature Genetics 13(4), pp. 464-468. (10.1038/ng0896-464)
Robertson, N., Deans, J., Fraser, M. and Compston, D. A. 1996. Multiple sclerosis in south Cambridgeshire: incidence and prevalence based on a district register. Journal of Epidemiology & Community Health 50(3), pp. 274-279. (10.1136/jech.50.3.274)
Robertson, N., Fraser, M., Deans, J., Clayton, D., Walker, N. and Compston, D. A. 1996. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain 119(2), pp. 449-455. (10.1093/brain/119.2.449)

1995

Wood, N. W., Sawcer, S. J., Kellar-Wood, H. F., Holmans, P. A., Clayton, D., Robertson, N. and Compston, D. A. 1995. The T-cell receptor beta locus and susceptibility to multiple sclerosis. Neurology 45(10), pp. 1859-1863. (10.1212/WNL.45.10.1859)
Wood, N. W., Sawcer, S. J., Kellar-Wood, H. F., Holmans, P. A., Clayton, D., Robertson, N. and Compston, D. A. 1995. Susceptibility to multiple sclerosis and the immunoglobulin heavy chain variable region. Journal of Neurology 242(10), pp. 677-682. (10.1007/BF00866919)
Robertson, N. P., Deans, J., Fraser, M. and Compston, D. A. 1995. Multiple sclerosis in the north Cambridgeshire districts of East Anglia. Journal of Neurology, Neurosurgery & Psychiatry 59(1), pp. 71-76. (10.1136/jnnp.59.1.71)
Chalmers, R. M., Robertson, N., Kellar-Wood, H., Compston, D. A. and Harding, A. E. 1995. Sequence of the human homologue of a mitochondrially encoded murine transplantation antigen in patients with multiple sclerosis. Journal of Neurology 242(5), pp. 332-334. (10.1007/BF00878877)
Kellar-Wood, H. F., Wood, N. W., Holmans, P. A., Clayton, D., Robertson, N. and Compston, D. A. 1995. Multiple sclerosis and the HLA-D region: linkage and association studies. Journal of Neuroimmunology 58(2), pp. 183-190. (10.1016/0165-5728(95)00015-T)
Robertson, N. and Compston, A. 1995. Surveying multiple sclerosis in the United Kingdom [Editorial]. Journal of Neurology, Neurosurgery & Psychiatry 58(1), pp. 2-6.
Compston, D. A., Kellar-Wood, H., Robertson, N. P., Sawcer, S. and Wood, N. W. 1995. Genes and susceptibility to multiple sclerosis [Editorial]. Acta Neurologica Scandinavica Supplementum 161, pp. 43-51. (10.1111/j.1600-0404.1995.tb05855.x)
Robertson, N., Wood, N., Holmans, P. A., Kellar-Wood, H. F., Sawcer, S. and Wood, N. W. 1995. Strategies for the identification of susceptibility genes in multiple sclerosis [Editorial]. The International Ms Journal 2, pp. 19-28.

1994

Wood, N. W., Holmans, P. A., Clayton, D., Robertson, N. P. and Compston, D. A. 1994. No linkage or association between multiple sclerosis and the myelin basic protein gene in affected sibling pairs. Journal of Neurology, Neurosurgery & Psychiatry 57(10), pp. 1191-1194. (10.1136/jnnp.57.10.1191)
Kellar-Wood, H., Robertson, N. P., Govan, G. G., Compston, D. A. and Harding, A. E. 1994. Leber's hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis. Annals of Neurology 36(1), pp. 109-112. (10.1002/ana.410360121)

Diddordebau ymchwil:

Sglerosis ymledol
Neuromyelitis optica
Geneteg
Epidemioleg
Ataxia

Aelod o'r panel niwrowyddoniaeth, cydlynydd swyddog arholiadau niwrowyddoniaeth a niwrowyddoniaeth blwyddyn tri ar gyfer MB canolradd

Addysg a chymwysterau

MBBS Llundain 1986
MRCP Llundain 1992
MD Llundain 1996
FRCP 2002

Proffil gyrfa

Athro Niwroleg Glinigol 2010 i'r presennol
Uwch Ddarlithydd mewn Niwroleg, Prifysgol Caerdydd 1999-2010
Niwrolegydd Ymgynghorol Anrhydeddus, Ysbyty Brenhinol Morgannwg, 1999 i'r presennol
Niwrolegydd Ymgynghorol Anrhydeddus, Ysbyty Athrofaol Cymru 1999 i'r presennol
Uwch Ddarlithydd mewn Niwroleg, Prifysgol Caergrawnt, 1997-1999
Darlithydd mewn Neurology, Prifysgol Caergrawnt, 1995-1997
Cofrestrydd Ymchwil Glinigol, Prifysgol Caergrawnt, 1992-1995

Parch Cyfoed

Llywydd Cymdeithas Etholedig Niwrolegwyr Prydain 2023-2025
Cymdeithas Trysoryddion Niwrolegwyr Prydain 2018-2023
Ymgynghorydd Meddygol i'r MS Society
Cynghorydd meddygol Ataxia UK
Cymdeithas Trysoryddion Anrhydeddus Niwrolegwyr Prydain 2018-gyfredol

Contact Details

RobertsonNP@caerdydd.ac.uk
+44 29218 45403
Prif Adeilad yr Ysbyty, Ystafell 4th Floor, B-C Link Corridor, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN

Manteision tymor hir therapi dwys yng nghamau cynnar MS

Yr Athro Neil Robertson (Translated he/him) MBBS FRCP MD

Trosolwyg

Cyhoeddiad

2025

2024

2023